Sha 2019 / Minted
Study ID(s) and Acronym(s)
Current Status of Trial
Melatonin // Placebo
Dosage and Duration
Participants were randomised to receive slow-release melatonin 4mg or placebo daily for five days.
Absolute Number of Participants
"Ten (melatonin n = 5, placebo n = 5) patients were included in the study. MDAS score on day 5 was similar between the two groups (10.3 +/- 8.3 vs 8.5 +/- 1.9 P = 0.6). The melatonin group had a longer total sleep time (292 +/- 41mins vs 211+/-80mins P = 0.075) and shorter sleep latency (113 +/- 46 mins vs 151 +/- 32mins P = 0.17), but the difference did not reach statistical significance. Conclusion(s): This trial confirmed the feasibility of conducting a randomised controlled study in an elderly delirious population. Although no statistically significant impact on delirium severity was demonstrated, the trend seen in improved sleep architecture in the melatonin group warrants further exploration in a larger study." Sha 2019